What Is BPC-157?
BPC-157, short for Body Protection Compound-157, is a synthetic peptide consisting of 15 amino acids. It is derived from a protective protein naturally found in human gastric juice. Unlike many synthetic compounds, BPC-157 is a partial sequence of a protein your body already produces — which is one reason researchers became interested in its therapeutic potential.
The peptide was first isolated and studied in the early 1990s by a research team led by Predrag Sikirić at the University of Zagreb. Since then, hundreds of animal studies and in-vitro experiments have investigated its effects on tissue repair, inflammation, and gut health. However, it's important to note that no large-scale human clinical trials have been completed to date.
Full name: Body Protection Compound-157. Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular weight: approximately 1,419 Da. Origin: derived from human gastric juice protein BPC.
BPC-157 is classified as a research peptide. It is not approved by the FDA or EMA for any medical use. People who use it typically obtain it from research chemical suppliers, though the regulatory landscape is shifting — more on that in our dedicated peptide legality guide.
How Does BPC-157 Work?
The exact mechanisms behind BPC-157's effects are still being mapped, but animal research has identified several pathways that the peptide appears to influence.
Angiogenesis and blood vessel formation
Multiple rodent studies suggest BPC-157 promotes the formation of new blood vessels (angiogenesis) at injury sites. Increased blood supply means more oxygen and nutrients reaching damaged tissue, which is a fundamental requirement for healing.
Growth factor modulation
Research indicates BPC-157 may upregulate the expression of growth hormone receptors and interact with the nitric oxide (NO) system. It has been shown in animal models to affect levels of several growth factors involved in wound healing and tissue remodeling.
Anti-inflammatory pathways
In rat studies, BPC-157 reduced markers of inflammation in various tissues including the gut, brain, and connective tissue. This appears to involve modulation of the inflammatory cytokine cascade, though the specific mechanisms differ depending on tissue type.
The gut-brain axis connection
One of the more intriguing areas of BPC-157 research involves its effects on the gut-brain axis. Animal studies have shown potential neuroprotective effects and interactions with the dopaminergic and serotonergic systems. This has led some researchers to investigate its potential in models of depression, anxiety, and brain injury — though all of this remains firmly in the preclinical stage.
The vast majority of BPC-157 studies have been conducted in rodent models. While results are promising, animal studies don't always translate to humans. Approach all claims with appropriate skepticism until controlled human trials are published.
What Does the Research Say?
As of 2026, there are approximately 100+ published studies involving BPC-157, predominantly in animal models. Here's what the most-cited research areas cover:
Tendon and ligament repair: Several rat studies have demonstrated accelerated healing of the Achilles tendon, quadriceps tendon, and medial collateral ligament following BPC-157 administration. These studies showed improvements in biomechanical strength and collagen organization.
Gut healing: Given its gastric origin, BPC-157 has been extensively studied in models of inflammatory bowel disease, gastric ulcers, and intestinal damage. Rodent models have shown reduced lesion size and improved mucosal integrity.
Muscle and bone: Animal studies have reported accelerated muscle healing after crush injuries and improved bone fracture repair, with enhanced osteogenic activity at fracture sites.
Organ protection: Research has shown protective effects in animal models of liver damage (including alcohol-induced), kidney injury, and cardiac damage from various toxins.
Neuroprotection: Multiple rodent studies have demonstrated effects on dopamine systems, with potential implications for conditions involving dopaminergic dysfunction. Researchers have also explored its effects in traumatic brain injury models.
Studied Benefits
Based on the available preclinical evidence, these are the most consistently observed effects in animal studies. Remember — "studied" does not mean "proven in humans."
| Benefit Area | Evidence Level | Notes |
|---|---|---|
| Tendon/ligament healing | Strong (animal) | Most-replicated finding across multiple labs |
| Gut mucosal protection | Strong (animal) | Consistent with its gastric origin |
| Muscle recovery | Moderate (animal) | Less studied than tendon repair |
| Anti-inflammatory | Moderate (animal) | Observed across multiple tissue types |
| Neuroprotection | Preliminary (animal) | Interesting but needs more research |
| Bone healing | Preliminary (animal) | Limited number of studies |
If you're interested in how BPC-157 compares to another popular healing peptide, see our BPC-157 vs TB-500 comparison. For those considering combining the two, check out our Wolverine Stack guide.
Side Effects & Safety
BPC-157 has shown a notably favorable safety profile in animal studies. Toxicology research in rodents has not identified an LD50 (lethal dose), which is unusual and suggests a wide therapeutic window — at least in animals.
Reported side effects from anecdotal human use (gathered from forums, clinics, and self-reported data) are generally mild and include nausea (typically at higher doses or on empty stomach), dizziness or lightheadedness shortly after injection, slight fatigue or lethargy, and localized injection site reactions including redness, swelling, or itching.
Without human clinical trials, we don't have reliable data on long-term safety, drug interactions, or effects in special populations (pregnant women, children, immunocompromised individuals). If you have a medical condition, consult a healthcare professional before considering any peptide.
Purity concerns
Perhaps the most significant practical risk with BPC-157 isn't the peptide itself — it's source quality. Because peptides are sold as research chemicals, they aren't subject to pharmaceutical-grade manufacturing standards. Contamination, degraded peptides, and mislabeled products are real concerns. Third-party testing (HPLC and mass spectrometry) is essential for anyone considering use.
Forms: Injection vs Oral vs Nasal
BPC-157 is available in several forms, each with different bioavailability profiles and practical considerations.
Subcutaneous injection
The most common method among self-experimenters. Typically administered subcutaneously near the injury site or in abdominal fat. Provides the most direct delivery to the bloodstream. Requires reconstitution of lyophilized powder with bacteriostatic water.
Oral (capsules)
BPC-157 is one of the few peptides that appears to remain active when taken orally — which makes sense given its gastric origin. Oral forms may be better suited for gut-related issues. Some researchers believe systemic effects may be reduced compared to injection, though this isn't definitively established.
Nasal spray
A newer delivery method that some users prefer for its convenience and potential for faster onset. Less studied than injection or oral routes.
For detailed dosing protocols across all forms, see our complete BPC-157 dosage guide.
Dosage Overview
There is no established human dosage for BPC-157. The ranges below are extrapolated from animal studies and anecdotal reports. This is not medical advice.
Dosing strategy, cycling, and protocol details are covered extensively in our dedicated dosage guide.
Legal Status
The legal status of BPC-157 varies significantly by country and has been shifting. In brief: it's not a controlled substance in most countries, but it's also not approved for human use. It typically falls into a regulatory gray area as a "research chemical."
Major regulatory developments include WADA (World Anti-Doping Agency) banning BPC-157 for athletes in competition, the FDA increasing scrutiny on peptide clinics and compounding pharmacies selling BPC-157, and Australia's TGA classifying it as a Schedule 4 prescription-only substance.
For a thorough breakdown of the legal landscape across different countries, see our Are Peptides Legal? guide.
Frequently Asked Questions
Is BPC-157 a steroid?
No. BPC-157 is a peptide — a short chain of amino acids. It has no androgenic, estrogenic, or anabolic-steroid properties. It does not affect testosterone or estrogen levels.
How quickly does BPC-157 work?
Anecdotal reports vary widely. Some users report feeling effects (reduced pain, improved gut symptoms) within days, while others describe a more gradual improvement over 2-4 weeks. Animal studies typically measure endpoints after 1-4 weeks of administration.
Can you take BPC-157 long term?
There is no long-term human safety data. Most anecdotal protocols run 4-12 weeks, sometimes with breaks between cycles. Without proper clinical data, the safety of extended use is unknown.
Does BPC-157 need to be injected near the injury?
This is debated. Some animal studies showed localized effects when injected near the injury site, while others demonstrated systemic effects regardless of injection location. Many users inject subcutaneously in abdominal fat for convenience and still report benefits.
What's the difference between BPC-157 and TB-500?
They're different peptides with overlapping but distinct mechanisms. BPC-157 originates from gastric juice and primarily influences angiogenesis and GI function. TB-500 (Thymosin Beta-4) is involved in actin regulation and cell migration. Many people use both together — a combination known as the Wolverine Stack. See our full comparison article for details.
Where can I buy BPC-157?
BPC-157 is sold by research peptide suppliers online. Quality varies enormously. Look for suppliers that provide third-party certificates of analysis (COA) showing purity via HPLC and mass spectrometry. We cover the legality aspects in our peptide legality guide.